Edward M. Basile - 29 Oct 2025 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Reporting relationship: Director
Issuer ticker: TMDX
Reported as of: 29 Oct 2025
Net transaction value: -$537,424
SEC form: 4
Accepted by SEC: 31 Oct 2025, 16:30:03 UTC
Prior SEC filing: 05 Aug 2025
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Gerardo Hernandez, Attorney-in-Fact

Key filing fact

Edward M. Basile filed Form 4 for TransMedics Group, Inc. (TMDX) on 31 Oct 2025.

Key facts

This page summarizes Edward M. Basile's Form 4 filing for TransMedics Group, Inc. (TMDX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Oct 2025, 16:30.

Change

Previous filing in this sequence was filed on 05 Aug 2025.
Current net transaction value: -$537,424.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001773661 Primary reporting owner

Basile Edward M

Relationship: Director
Address: C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER
Signature: By: /s/ Gerardo Hernandez, Attorney-in-Fact
Signature date: 31 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMDX transaction

Common Stock

Options Exercise

Transaction value: $2,899
Shares: +4,142
Change %: +145%
Price: $0.7000
Shares after: 7,008
Date: 29 Oct 2025
Ownership: Direct
Footnotes: F1

TMDX transaction

Common Stock

Sale

Transaction value: $540,324
Shares: -4,142
Change %: -59%
Price: $130.45
Shares after: 2,866
Date: 29 Oct 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TMDX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -4,142
Change %: -100%
Price
Shares after: 0
Date: 29 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,142
Exercise price: $0.7000
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 6, 2024.

Footnote F2

The option is fully vested.

Footnote F3

The Stock Option reported herein as being disposed of is an option to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.